Zacks Investment Research upgraded shares of Odonate Therapeutics (NASDAQ:ODT) from a sell rating to a hold rating in a research note released on Saturday.

According to Zacks, “Odonate Therapeutics, LLC is a pharmaceutical company. It engaged in the development of therapeutics to improve and extend the lives of patients with cancer. The company focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer. Odonate Therapeutics, LLC is based in SAN DIEGO, United States. “

Separately, ValuEngine raised shares of Odonate Therapeutics from a sell rating to a hold rating in a research report on Wednesday, May 2nd. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Odonate Therapeutics presently has a consensus rating of Hold and an average price target of $31.00.

Shares of NASDAQ ODT opened at $19.03 on Friday. Odonate Therapeutics has a 1 year low of $15.15 and a 1 year high of $32.00. The stock has a market cap of $511.75 million and a P/E ratio of -8.24.

Odonate Therapeutics (NASDAQ:ODT) last issued its quarterly earnings results on Monday, July 30th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.03. equities analysts anticipate that Odonate Therapeutics will post -3.42 earnings per share for the current year.

In other Odonate Therapeutics news, CEO Kevin C. Tang purchased 22,810 shares of the stock in a transaction that occurred on Wednesday, August 15th. The stock was bought at an average cost of $18.93 per share, with a total value of $431,793.30. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 49.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Schwab Charles Investment Management Inc. lifted its position in Odonate Therapeutics by 19.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 34,137 shares of the company’s stock valued at $754,000 after acquiring an additional 5,601 shares during the period. The Manufacturers Life Insurance Company purchased a new position in Odonate Therapeutics during the 1st quarter valued at about $128,000. California State Teachers Retirement System purchased a new position in Odonate Therapeutics during the 1st quarter valued at about $218,000. Redmile Group LLC lifted its position in Odonate Therapeutics by 2.8% during the 2nd quarter. Redmile Group LLC now owns 610,600 shares of the company’s stock valued at $13,482,000 after acquiring an additional 16,400 shares during the period. Finally, Goldman Sachs Group Inc. purchased a new position in Odonate Therapeutics in the fourth quarter worth about $660,000. 83.42% of the stock is owned by institutional investors.

Odonate Therapeutics Company Profile

Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc also conducting a Phase III study in MBC, which is known as CONTESSA.

Read More: Diversification in Your Portfolio

Get a free copy of the Zacks research report on Odonate Therapeutics (ODT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.